Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An update from SSY Group ( (HK:2005) ) is now available.
SSY Group Limited has announced that its product, Nimodipine, has received approval from the National Medical Products Administration of China to be marketed as a bulk drug. This development marks a significant step in the company’s product offerings, potentially enhancing its market position and providing new opportunities for growth in the pharmaceutical sector.
More about SSY Group
SSY Group Limited operates in the pharmaceutical industry, focusing on the development and production of drugs. The company is involved in creating treatments for various medical conditions, including ischemic cerebrovascular disease and hypertension.
YTD Price Performance: -0.47%
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.25B
For detailed information about 2005 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue